Hennie G. Raterman

Alkmaar, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Osteoimmunology: Can We Prevent Bone Loss in Rheumatoid Arthritis with Modern Antirheumatic Drugs?

Osteoimmunology: Can We Prevent Bone Loss in Rheumatoid Arthritis with Modern Antirheumatic Drugs?

Journal: Calcified tissue international
Published: December 21, 2025

Vitamin D in inflammatory rheumatic diseases: still a challenge.

Vitamin D in inflammatory rheumatic diseases: still a challenge.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Published: May 11, 2025

Hypothyroidism and rheumatoid arthritis: Missing a link?

Hypothyroidism and rheumatoid arthritis: Missing a link?

Journal: Journal of internal medicine
Published: December 20, 2023

Determination of the Value of Color Doppler Ultrasound in Patients With a Clinical Suspicion of Giant Cell Arteritis.

Determination of the Value of Color Doppler Ultrasound in Patients With a Clinical Suspicion of Giant Cell Arteritis.

Journal: ACR open rheumatology
Published: May 21, 2023

High Frequency of Foot Insufficiency Fractures in Patients With Rheumatic Diseases Referred for Magnetic Resonance Imaging: What Is the Clinical Relevance?

High Frequency of Foot Insufficiency Fractures in Patients With Rheumatic Diseases Referred for Magnetic Resonance Imaging: What Is the Clinical Relevance?

Journal: The Journal of rheumatology
Published: March 15, 2023

Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.

Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.

Journal: Annals of the rheumatic diseases
Published: February 21, 2023

The Effect of Anti-rheumatic Drugs on the Skeleton.

The Effect of Anti-rheumatic Drugs on the Skeleton.

Journal: Calcified tissue international
Published: April 22, 2022

Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Journal: Nature reviews. Rheumatology
Published: February 09, 2022

Mitral valve disease in ankylosing spondylitis: an autoimmune disease manifestation? A case report.

Mitral valve disease in ankylosing spondylitis: an autoimmune disease manifestation? A case report.

Journal: European heart journal. Case reports
Published: December 28, 2021

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.

Journal: Annals of the rheumatic diseases
Published: December 02, 2021

Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.

Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.

Journal: Drugs
Published: August 05, 2021

Correction to: Management of glucocorticoid-induced osteoporosis.

Correction to: Management of glucocorticoid-induced osteoporosis.

Journal: Aging clinical and experimental research
Published: July 15, 2021
Showing 1-12 of 31

Last Updated: 09/26/2026